Conjugation and Labeling Procedures for Isothiocyanato Derivatives
The preparation of DTPA coupled antibodies radiolabeled with metallic radionuclides: an improved method. D. J. Hnatowich, R. L. Childs, D. Lanteigne, A. Najafi, J. Immunol. Methods, 1983, 65, 147-157.
Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamido reagents, methods of analysis, and subsequent addition of metal ions . C. F. Meares, M. J. McCall, D. T. Reardan, D. A. Goodwin, C. I. Diamanti, McTigue Anal. Biochem. 1984, 142, 68-78.
Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl) diethylenetriaminepentaacetic acid ligands to immunoglobulin . S. Mirzadeh, M. W. Brechbiel R. W. Atcher, O. A. Gansow Bioconjugate Chem. 1990,1, 59-65.
Macrocyclic chelates of radiometals for diagnosis and therapy . C. F. Meares, M. K. Moi, H. Diril, D. L. Kukis, M. J. McCall, S. V. Deshapnde, S. J. DeNardo, D. Snook, A. A. Epenetos Br. J. Cancer1990, Suppl. 10, 21-26.
An improved method for labeling monoclonal antibodies with samarium-153: use of the bifunctional chelate 2-(p-isothiocyanatobenzyl)-6-methyldiethylenetriaminepentaacetic acid . M. E. Izard, G. R. Boniface, K. L. Hardiman, M. W. Brechbiel, O. A. Gansow, K. Z. Walkers Bioconjugate Chem. 1992, 3, 346-350.
A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. T. K. Nikula; M. J. Curcio; M. W. Brechbiel; O. A. Gansow; R. D. Finn; D. A. Scheinberg Nucl. Med. Biol. 1995, 22, 387-90.
Evaluation of a new DTPA-derivative chelator: comparative biodistribution and imaging studies of indium-111-labeled B3 monoclonal antibody in athymic mice bearing human epidermoid carcinoma xenographs. L. Camera, S. Kinyua, K. Garmestani, L. H. Pai, M. W. Brechbiel, O. A. Gansow, C. H. Paik, I. Pastan, J. A. Carrasquillo Nucl. Med. Biol . 1993, 20, 955-62.
Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates. D. L. Kukis, S. J. DeNardo, G. L. DeNardo, R. T. O’Donnell, C. F. Meares J. Nucl. Med.1998, 39, 2105-2110.
Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. I. Verel, G. W. M. Visser, R. Boellaard, O. C. Boerman, J. van Eerd, G. B. Snow, A. A. Lammertsma, G.A.M.S van Dongen J. Nucl. Med. 2003, 44, 1663-1670.
Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA). L. Camera, S. Kinuya, K. Garmestani, M. W. Brechbiel, C. Wu, L. H. Pai, T. J. McMurry, O. A. Gansow, I. Pastan Eur. J. Nucl. Med.1994, 21, 640-646.
Improved in vivo stability and tumor targeting of bismuth labeled antibody. C. L. Ruegg, W. T. Anderson-berg, M. W. Brechbiel, S. Mirzadeh, O. A. Gansow, M. Strand Cancer Res. 1990, 50, 4221-4226.
Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft bearing nude mice. I. Verel, G. W. M. Visser, R. Boellaard, O. C. Boerman, J. van Eerd, G. B. Snow, A. A. Lammertsma, G. A. M. S. van Dongen, J. Nucl. Med.2003, 44, 1663-1670
Specific localization, gamma camera imaging and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871in SK-MEL-28 melanoma xenografts. F. T. Lee, A. Rigopoulos, C. Hall Cancer Res. 2001, 61, 4474-4482.
Targeting primary human Ph+ B-cell precursor leukemia-engrafted SCID mice usning radiolabeled anti-CD19 monoclonal antibodies. P. Mitchell, F. T. Lee, C. Hall, A. Rigopoulos, F. E. Smyth, A. M. Hekman, G. M. van Schijndel, R. Powles, M. W. Brechbiel, A. M. Scott, J. Nucl. Med. 2003, 44, 1105-1112. (CHX)
Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody. H. Kobayashi, C. Wu, M. K. Kim, C. H. Paik, J. A. Carrasquillo, M. W. Brechbiel, Bioconjugate Chem. 1999, 10, 103-111.
Pharmacokinetics, dosimetry and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. M. Miederer, M. R. McDevitt, G. Sgouros, K. Kramer, N. K. V. Cheung, D. A. Scheinberg, J. Nucl. Med. 2004, 45, 129-137.
Comparison of 1,4,7,10-tetraazacyclododecane-N,N’,N”,N”’-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts. G. L. DeNardo, L. A. Kroger, C. F. Meares, C. M. Richman, Q. Salako, S. Shen, K. R. Lamborn, J. J. Peterson, L. A. Miers, G. R. Zhong, S. J. DeNardo Clinical Cancer Research1998, 4, 2483-90.
Labeling anti-HER2/neu monoclonal antibodies with 111In and 90Y using a bifunctional DTPA chelating agent . M. J. Blend, J. J. Stastny, S. M. Swanson, M. W. Brechbiel Cancer Biotherapy & Radiopharmaceuticals2003, 18, 355-363.
Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry . T. K. Nikula, M. R. McDevitt, R. D. Finn, C. Wu, R. W. Kozak, K. Garmestani, M. W. Brechbiel, M. J. Curcio, C. G. Pippin; L. Tiffany-Jones, M. W. Sr. Geerlings, C. Apostolidis, R. Molinet, M. W. Jr. Geerlings, O. A. Gansow, D. A. Scheinberg J. Nucl. Med. 1999, 40, 166-76.
Pretargeted alpha-emitting radioimmunotherapy using 213Bi 1,4,7,10-tetraazacyclododecane-N,N’,N”,N”’-tetraacetic Acid-biotin. Z. Yao, M. Zhang, K. Garmestani, D. B. Axworthy, R. W. Mallett, A. R. Fritzberg, L. J. Theodore, P. S. Plascjak, W. C. Eckelman, T. A. Waldmann, I. Pastan, C. H. Paik, M. W. Brechbiel, J. A. Carrasquillo Clinical Cancer Research2004, 10, 3137-3146.
Analytical Methods, Chelation and Stability Measurements
Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates . C. G. Pippin, T. A. Parker, T. J. McMurry, M, W. Brechbiel Bioconjugate Chem.1992, 3, 342-5.
Development of a spectroscopic assay for bifunctional ligand-protein conjugates based on copper. E. D. Brady, H.-S. Chong, D. E. Milenic, M. W. Brechbiel Nucl Med. Biol.2004, 31, 795-802.
Solution dynamics and stability of lanthanide(III) (S)-2-(p-Nitrobenzyl)DOTA complexes. M. Woods, Z. Kovacs, R. Kiraly, E. Bruecher, S. Zhang, A. Dean Sherry Inorg. Chem.2004, 43, 2845-2851.
Yttrium-90 chelation properties of tetraazatetraacetic acid macrocycles, diethylenetriaminepentaacetic acid analogues, and a novel terpyridine acyclic chelator . J. B. Stimmel, M. E. Stockstill, F. C. Jr. Kull Bioconjugate chemistry 1995, 6, 219-25.
Physical parameters and biological stability of yttrium(III) diethylenetriaminepentaacetic acid derivative conjugates . T. J. McMurry, C. G. Pippin, C. Wu, K. A. Deal M. W. Brechbiel, S. Mirzadeh, O. A. Gansow J. Med. Chem. 1998, 41, 3546-3549
Samarium-153 and lutetium-177 chelation properties of selected macrocyclic and acyclic ligands . J. B. Stimmel, F. C. Jr. Kull Nucl Med. Biol.1998, 25, 117-25.
Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies. H. Kobayashi, C. Wu, T. M. Yoo, B. F. Sun, D. Drumm, I. Pastan, C. H. Paik, O. A. Gansow, J. A. Carrasquillo, M. W. Brechbiel J. Nucl. Med.1998. 39, 829-36.
The stability in liver homogenates of indium-111 and yttrium-90 attached to antibody via two popular chelators. G. Mardirossian, C. Wu, D. J. Hnatowich Nucl. Med. Biol. 1993, 20, 65-74.
In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts . M. Roselli, D. E. Milenic, M. W. Brechbiel, S. Mirzadeh, C. G. Pippin, O. A. Gansow, D. Colcher, J. Schlom Cancer Biotherapy & Radiopharmaceuticals1999, 14, 209-20.
Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. L. Camera, S. Kinuya, K. Garmestani, C. Wu, M. W. Brechbiel,L. H. Pai, T. J. McMurry, O. A. Gansow, I. Pastan J. Nucl Med1994, 35, 882-889.
Application of DOTA-tris(tert-Bu) in the Synthesis of DOTA-peptides
Solid-phase synthesis of DOTA-peptides. L. M. De Leon-Rodriguez, Z. Kovacs, G. R. Dieckmann, A. D. Sherry, Chem.Eur. J., 200410, 1149-1155.
Magnetic resonance imaging detects a specific peptide-protein binding event . L. M. De León-Rodriguez, A. Ortiz, A. Weiner, S. Zhang, Z. Kovacs, T.J. Kodadek, A. D. Sherry, J. Am. Chem. Soc.2002, 124, 3514-3515.
Macrocyclic chelators with paramagnetic cations are internalized into mammalian cells via a HIV-Tat derived membrane translocation peptide. R. Bhorade, R. Weissleder, T. Nakakoshi, A. Moore, C.-H. Tung Bioconjugate Chem. 2000, 11, 301-305.
Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. T. J. Hoffman, H. Gali, C. J. Smith, G. L. Sieckman, D. L. Hayes, N. K. Owen, W. A. Volkert J. Nucl. Med. 2003, 44, 823-831.
Poly(L-glutamic acid) Gd(III)-DOTA conjugate with a degradable spacer for magnetic resonance imaging. Z. R. Lu, X. Wang, D. L. Parker, K. C. Goodrich, H. R. Buswell Bioconjugate Chem. 2003, 14, 715-719.
Chemical synthesis of Escherichia Coli ST h analogues by regioselectivedisulfide bond formation: biological evaluation of an 111In-DOTA-Phe 19-ST h analogue for specific targeting of human colon cancers. H. Gali, G. L. Sieckman, T. J. Hoffman, N. K. Owen, D. G. Mazuru, L. R. Forte, W. A. Volkert, Bioconjugate Chem. 2002, 13, 224-231.
Evaluation of cleavable (Tyr 3)-octreotate derivatives for longer intracellular probe residence. P. A. Whetstone, H. Akizawa, C. F. Meares, Bioconjugate Chem . 2004, 15, 647-657.
Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. A. Heppeler, S. Froidevaux, H. R. Maecke, E. Jermann, M. Behe, P. Powell, M. Hennig, Chem. Eur. J.1999, 5, 1974-1981. (DOTA-tris-tBu)
Coupling with DOTA and Activated Esters of DOTA
An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinidyl DOTA. M. R. Lewis, J. Y. Kao, A. L. Anderson, J. E. Shively, A. Raubitschek, Bioconjugate Chem . 2001, 12, 320-324.
Vinyl sulfone bifunctional derivatives of DOTA allow sulfhydryl or amino-directed coupling to antibodies. Conjugates retain immunoreactivity and have similar biodistributions. L. Li, S. W. Tsai, A.-L. Anderson, D. A. Keire, A. A. Raubitschek, J. E. Shively; Bioconjugate Chem. 2002, 13, 110-115.
MicroPET and autoradiographic imaging of breast cancer a V-integrin expression using 18F- and 64Cu-labeled RGD peptide. X. Chen, R. Park, M. Tohme, A. H. Shahinian, J. R. Bading, P. S. Conti Bioconjugate Chem. 2004, 15, 41-49.
Conformation and structure of polymeric contrast agents for medical imaging. E. E. Uzgiris, H. Cline, B. Moasser, B. Grimmond, M. Amaratunga, J. F. Smith, G. Goddard, Biomacromolecules2004, 5, 54-61.
Conjugation of DOTA using isolated phenolic active esters: the labeling and biodistribution of albumin as blood pool marker. W. Mier, J. Hoffend, S. Kramer, J. Schuhmacher, W. E. Hull, M. Eisenhut, U. Haberkorn Bioconjugate Chem . 2005, 16, 237?-240
Direct synthesis of [DOTA-DPhe 1]-octreotide and [DOTA-DPhe 1, Tyr 3]-octreotide (SMT487): Two conjugates for systemic delivery of radiotherapeutical nuclides to somatostatin receptor positive tumors in man. R Albert, P. Smith-Jones, B. Soltz, C. Simeon, H. Knecht, C. Bruns, J. Pless Bioorg. Med. Chem. Lett. 1998, 8, 1207 -1210.
TmDOTP as an in vivo Temperature Probe
Brain temperature measured by 1H-NMR in conjunction with a lanthanide complex. H. K. F. Trubel, P. K. Maciejewski, J. H. Farber, F. Hyder J. Appl. Physiol. 2003, 94, 1641-1649.
Simultaneous measurements of temperature and pH in Vivo using NMR in conjuction with TmDOTP5-.Y. Sun, M Sugawara, R. V. Mulkern, K. Hynyen, S. Mochizuki, M. Albert, C. S. Zuo, NMR Biomed. 2000, 13, 460-466.
